It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
Lower showed no clear difference in mortality, near term corrected age or discharge compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
Lower showed no clear difference in neurodevelopmental disability compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
Lower showed no clear difference in intubation in the delivery room compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
Lower showed no clear difference in severe retinopathy of prematurity (≥ stage 3) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
Lower showed no clear difference in severe intraventricular haemorrhage (grade 3 or 4) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
Lower showed no clear difference in necrotising enterocolitis compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
It is very uncertain whether lower changes chronic lung disease (36 weeks' corrected age) compared with higher oxygen concentrations titrated to target oxygen saturations… (very low certainty).
Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).
Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).
It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).